• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Zoloft (sertraline HCl)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Zoloft (sertraline HCl)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: https://www.zoloft.com/

Currently Enrolling Trials

    Show More

    General Information

    Zoloft (sertraline HCl) is a selective serotonin reuptake inhibitor.

    Zoloft has been approved for:

    • major depressive disorder
    • obsessive-compulsive disorder
    • panic disorder
    • Premenstrual dysphoric disorder
    • Post-traumatic stress disorder (PTSD)
    • Social anxiety disorder (SAD)

    Clinical Results

    In clinical trials with adult patients, Zoloft demonstrated significant reduction in frequency of panic attacks without regard to age, gender or race. Patients suffering from panic disorder experience recurrent, unexpected panic attacks. The more common symptoms include heart palpitations, sensations of shortness of breath, dizziness and fear of losing control or going crazy. Panic attacks, or the fear of them, can also result in worry, concern or even dramatic behavioral and lifestyle changes.

    The approval of Zoloft for the treatment of PMDD is supported by two placebo-controlled trials involving 532 women diagnosed with the disorder. Zoloft was significantly more effective in improving emotional and behavioral symptoms of PMDD than placebo, regardless if the drug was taken continously or only during the premenstrual phase of the menstrual cycle. These symptoms included feelings of being depressed, hopeless or overwhelmed, and being angry or irritable and having conflicts with others. Those who were admistered Zoloft every day also noted improvement in physical symptoms including breast tenderness, bloating and headache.

    Side Effects

    Adverse events associated with the use of Zoloft may include (but are not limited to) the following:

    • Upset stomach
    • Trouble sleeping
    • Diarrhea
    • Abdominal pain
    • Dry mouth
    • Sexual dysfunction

    Mechanism of Action

    Zoloft (sertraline HCl) is a selective serotonin reuptake inhibitor. Zoloft helps correct the chemical imbalance of serotonin in the brain. The effectiveness of Zoloft is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (5HT). Serotonin is a naturally occurring chemical in the brain that is involved in the transmission of messages between nerve cells.

    Approval Date: 1997-07-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing